NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









RIGImmune Inc.

RIGImmune Inc.

Private
Farmington, ConnecticutHealthcare & Life Scienceshttps://rigimmune.com/

Last Round

Series A

Apr 1, 2024

Est. Valuation

$18.25M

Total Funding Raised

$15M

Company Overview

RIGImmune Inc. is a biopharmaceutical company developing a new class of RNA immunotherapeutics that selectively activate the innate immune sensor RIG-I to treat diseases caused by RNA viruses and to induce antitumor immune responses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticsbiotechnologyRIG-I agonistdrug delivery platformmRNA therapeuticsbiopharmarespiratory disease treatmentnano-emulsion deliveryoncology therapeuticsinnate immune pathwaypreclinical drug developmentinhaled drug deliverydrug discoverynon-lipid nanoparticlebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RIGImmune Inc. Comparables

Compare RIGImmune Inc. with similar companies based on industry and business-model similarity.

RIGImmune Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merck & Co., Inc.
77%
Xanadu Bio
77%
NorthLinks Bio
76%

RIGImmune Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 1, 2024
GrantDec 7, 2022
VC RoundDec 7, 2022
VC RoundSep 15, 2022
SeedDec 10, 2021

Key People

Founding team and executive leadership

Jag Shur

Chief Technology Officer Head of Drug Delivery

Executive Team

RIGImmune Inc. Investors

Notable investors and investment history

RIGImmune Inc. investors
InvestorRounds
Rivermount VenturesVC Round
Bill & Melinda Gates FoundationVC Round, Grant
Yale VenturesSeed
F-Prime CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    Monthly visitors increased 219% MoM.

  • Sep 15, 2022

    Round led by F-Prime Capital

RIGImmune Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

RIGImmune Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about RIGImmune Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersFarmington, Connecticut
Employee Range10
Year Founded2020
Last FundingApr 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.